Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review
Psoriasis and vitiligo are 2 multifactorial immune-mediated diseases, partially sharing pathogenetic underpinnings. Their coexistence in the same patient, although uncommon, is documented in the literature. Further, several cases of vitiligo induced by biological drugs in psoriatic patients are repo...
Gespeichert in:
| Veröffentlicht in: | Case Reports in Dermatology 2021-07, Vol.13 (2), p.372-378 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 378 |
|---|---|
| container_issue | 2 |
| container_start_page | 372 |
| container_title | Case Reports in Dermatology |
| container_volume | 13 |
| creator | Burlando, Martina Muracchioli, Andrea Cozzani, Emanuele Parodi, Aurora |
| description | Psoriasis and vitiligo are 2 multifactorial immune-mediated diseases, partially sharing pathogenetic underpinnings. Their coexistence in the same patient, although uncommon, is documented in the literature. Further, several cases of vitiligo induced by biological drugs in psoriatic patients are reported. However, improvements in psoriasis and pre-existing vitiligo after the introduction of biological therapy are also described. To date, anti-TNF-alpha is the most cited group of biological drugs that induce new-onset vitiligo or progression of pre-existence vitiligo in psoriatic patients. Even anti-IL-12/23 class would seem to induce vitiligo (as in our case) or even worse it. Anti-IL-17 drugs induce a progression of pre-existing vitiligo while, to date, no cases are reported in literature considering anti-IL-23 class. |
| doi_str_mv | 10.1159/000514198 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2570443854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A674781309</galeid><doaj_id>oai_doaj_org_article_ada6cee5c07e408f9c16618d40125773</doaj_id><sourcerecordid>A674781309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-aaede941e3b9c648c2f00d4d7f649ee93714530a6ae78ea1175fe55b10fa25ef3</originalsourceid><addsrcrecordid>eNptkc9rFDEUgAdRbK0evHsY6Eno1mTya-KhULdVi0VFqtfwNnmZZt2djMnslv73pp2yWJAcEt773peXvKp6TckxpUK_I4QIyqlun1T7VMpmJoVUT_8571Uvcl4SIrWQ7Hm1xzinTDGxX335nmMKkEM-qn-FMaxCF49q6F39IcRV7IKtr64xwXD7vp5DxvoHDjGN98RXSAnGsL0LbgPevKyeeVhlfPWwH1Q_P55fzT_PLr99upifXs6saPQ4A0CHmlNkC20lb23jCXHcKS-5RtRMUS4YAQmoWgRKlfAoxIISD41Azw6qi8nrIizNkMIa0q2JEMx9IKbOQBqDXaEBB9IiCksUctJ6bcuf0NZxQhuhFCuuk8k1bBZrdBb7McHqkfRxpg_Xpotb0zKmBVVFcPggSPHPBvNolnGT-vJ-U24gnLNW8EIdT1QHpavQ-1hktiyH62Bjjz6U-KlUXLWUEV0K3k4FNsWcE_pdS5SYu6Gb3dAL-2Zif0PqMO3IXfrwv-n52flEmMF59heXXrEK</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570443854</pqid></control><display><type>article</type><title>Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Karger Open Access</source><creator>Burlando, Martina ; Muracchioli, Andrea ; Cozzani, Emanuele ; Parodi, Aurora</creator><creatorcontrib>Burlando, Martina ; Muracchioli, Andrea ; Cozzani, Emanuele ; Parodi, Aurora</creatorcontrib><description>Psoriasis and vitiligo are 2 multifactorial immune-mediated diseases, partially sharing pathogenetic underpinnings. Their coexistence in the same patient, although uncommon, is documented in the literature. Further, several cases of vitiligo induced by biological drugs in psoriatic patients are reported. However, improvements in psoriasis and pre-existing vitiligo after the introduction of biological therapy are also described. To date, anti-TNF-alpha is the most cited group of biological drugs that induce new-onset vitiligo or progression of pre-existence vitiligo in psoriatic patients. Even anti-IL-12/23 class would seem to induce vitiligo (as in our case) or even worse it. Anti-IL-17 drugs induce a progression of pre-existing vitiligo while, to date, no cases are reported in literature considering anti-IL-23 class.</description><identifier>ISSN: 1662-6567</identifier><identifier>EISSN: 1662-6567</identifier><identifier>DOI: 10.1159/000514198</identifier><identifier>PMID: 34413735</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>biologic therapy ; Biological products ; Case and Review ; Case reports ; Cytokines ; Development and progression ; Disease ; Drugs ; Immunotherapy ; Monoclonal antibodies ; narrative review ; Patients ; Penis ; Psoriasis ; TNF inhibitors ; Tumor necrosis factor ; Vitiligo</subject><ispartof>Case Reports in Dermatology, 2021-07, Vol.13 (2), p.372-378</ispartof><rights>2021 The Author(s). Published by S. Karger AG, Basel</rights><rights>COPYRIGHT 2021 S. Karger AG</rights><rights>2021 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-aaede941e3b9c648c2f00d4d7f649ee93714530a6ae78ea1175fe55b10fa25ef3</citedby><orcidid>0000-0002-4381-6718</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339517/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339517/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27612,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Burlando, Martina</creatorcontrib><creatorcontrib>Muracchioli, Andrea</creatorcontrib><creatorcontrib>Cozzani, Emanuele</creatorcontrib><creatorcontrib>Parodi, Aurora</creatorcontrib><title>Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review</title><title>Case Reports in Dermatology</title><addtitle>Case Rep Dermatol</addtitle><description>Psoriasis and vitiligo are 2 multifactorial immune-mediated diseases, partially sharing pathogenetic underpinnings. Their coexistence in the same patient, although uncommon, is documented in the literature. Further, several cases of vitiligo induced by biological drugs in psoriatic patients are reported. However, improvements in psoriasis and pre-existing vitiligo after the introduction of biological therapy are also described. To date, anti-TNF-alpha is the most cited group of biological drugs that induce new-onset vitiligo or progression of pre-existence vitiligo in psoriatic patients. Even anti-IL-12/23 class would seem to induce vitiligo (as in our case) or even worse it. Anti-IL-17 drugs induce a progression of pre-existing vitiligo while, to date, no cases are reported in literature considering anti-IL-23 class.</description><subject>biologic therapy</subject><subject>Biological products</subject><subject>Case and Review</subject><subject>Case reports</subject><subject>Cytokines</subject><subject>Development and progression</subject><subject>Disease</subject><subject>Drugs</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>narrative review</subject><subject>Patients</subject><subject>Penis</subject><subject>Psoriasis</subject><subject>TNF inhibitors</subject><subject>Tumor necrosis factor</subject><subject>Vitiligo</subject><issn>1662-6567</issn><issn>1662-6567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkc9rFDEUgAdRbK0evHsY6Eno1mTya-KhULdVi0VFqtfwNnmZZt2djMnslv73pp2yWJAcEt773peXvKp6TckxpUK_I4QIyqlun1T7VMpmJoVUT_8571Uvcl4SIrWQ7Hm1xzinTDGxX335nmMKkEM-qn-FMaxCF49q6F39IcRV7IKtr64xwXD7vp5DxvoHDjGN98RXSAnGsL0LbgPevKyeeVhlfPWwH1Q_P55fzT_PLr99upifXs6saPQ4A0CHmlNkC20lb23jCXHcKS-5RtRMUS4YAQmoWgRKlfAoxIISD41Azw6qi8nrIizNkMIa0q2JEMx9IKbOQBqDXaEBB9IiCksUctJ6bcuf0NZxQhuhFCuuk8k1bBZrdBb7McHqkfRxpg_Xpotb0zKmBVVFcPggSPHPBvNolnGT-vJ-U24gnLNW8EIdT1QHpavQ-1hktiyH62Bjjz6U-KlUXLWUEV0K3k4FNsWcE_pdS5SYu6Gb3dAL-2Zif0PqMO3IXfrwv-n52flEmMF59heXXrEK</recordid><startdate>20210716</startdate><enddate>20210716</enddate><creator>Burlando, Martina</creator><creator>Muracchioli, Andrea</creator><creator>Cozzani, Emanuele</creator><creator>Parodi, Aurora</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4381-6718</orcidid></search><sort><creationdate>20210716</creationdate><title>Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review</title><author>Burlando, Martina ; Muracchioli, Andrea ; Cozzani, Emanuele ; Parodi, Aurora</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-aaede941e3b9c648c2f00d4d7f649ee93714530a6ae78ea1175fe55b10fa25ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>biologic therapy</topic><topic>Biological products</topic><topic>Case and Review</topic><topic>Case reports</topic><topic>Cytokines</topic><topic>Development and progression</topic><topic>Disease</topic><topic>Drugs</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>narrative review</topic><topic>Patients</topic><topic>Penis</topic><topic>Psoriasis</topic><topic>TNF inhibitors</topic><topic>Tumor necrosis factor</topic><topic>Vitiligo</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burlando, Martina</creatorcontrib><creatorcontrib>Muracchioli, Andrea</creatorcontrib><creatorcontrib>Cozzani, Emanuele</creatorcontrib><creatorcontrib>Parodi, Aurora</creatorcontrib><collection>Karger Open Access</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case Reports in Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burlando, Martina</au><au>Muracchioli, Andrea</au><au>Cozzani, Emanuele</au><au>Parodi, Aurora</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review</atitle><jtitle>Case Reports in Dermatology</jtitle><addtitle>Case Rep Dermatol</addtitle><date>2021-07-16</date><risdate>2021</risdate><volume>13</volume><issue>2</issue><spage>372</spage><epage>378</epage><pages>372-378</pages><issn>1662-6567</issn><eissn>1662-6567</eissn><abstract>Psoriasis and vitiligo are 2 multifactorial immune-mediated diseases, partially sharing pathogenetic underpinnings. Their coexistence in the same patient, although uncommon, is documented in the literature. Further, several cases of vitiligo induced by biological drugs in psoriatic patients are reported. However, improvements in psoriasis and pre-existing vitiligo after the introduction of biological therapy are also described. To date, anti-TNF-alpha is the most cited group of biological drugs that induce new-onset vitiligo or progression of pre-existence vitiligo in psoriatic patients. Even anti-IL-12/23 class would seem to induce vitiligo (as in our case) or even worse it. Anti-IL-17 drugs induce a progression of pre-existing vitiligo while, to date, no cases are reported in literature considering anti-IL-23 class.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>34413735</pmid><doi>10.1159/000514198</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4381-6718</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-6567 |
| ispartof | Case Reports in Dermatology, 2021-07, Vol.13 (2), p.372-378 |
| issn | 1662-6567 1662-6567 |
| language | eng |
| recordid | cdi_proquest_journals_2570443854 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Karger Open Access |
| subjects | biologic therapy Biological products Case and Review Case reports Cytokines Development and progression Disease Drugs Immunotherapy Monoclonal antibodies narrative review Patients Penis Psoriasis TNF inhibitors Tumor necrosis factor Vitiligo |
| title | Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A03%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriasis,%20Vitiligo,%20and%20Biologic%20Therapy:%20Case%20Report%20and%20Narrative%20Review&rft.jtitle=Case%20Reports%20in%20Dermatology&rft.au=Burlando,%20Martina&rft.date=2021-07-16&rft.volume=13&rft.issue=2&rft.spage=372&rft.epage=378&rft.pages=372-378&rft.issn=1662-6567&rft.eissn=1662-6567&rft_id=info:doi/10.1159/000514198&rft_dat=%3Cgale_proqu%3EA674781309%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570443854&rft_id=info:pmid/34413735&rft_galeid=A674781309&rft_doaj_id=oai_doaj_org_article_ada6cee5c07e408f9c16618d40125773&rfr_iscdi=true |